CJC-1295 No DAC & Ipamorelin Protocol — Fat Loss Guide
The most common mistake people make with CJC-1295 no DAC and ipamorelin isn't the dosing. It's expecting GH secretagogues to replace caloric discipline. These peptides amplify your body's existing growth hormone (GH) pulses, which increases lipolysis (fat breakdown) and preserves lean mass during a deficit. But they don't override thermodynamics. A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that GH secretagogue use without caloric restriction produced negligible fat loss compared to placebo, while the combination of GH secretagogues and a 20% caloric deficit produced 3.2× greater visceral fat reduction than diet alone.
Our team has worked with researchers using peptide protocols for metabolic studies. The gap between doing it right and doing it wrong comes down to three things most guides never mention: dosing synchronization with endogenous GH pulses, nutrient timing around injections, and realistic timeline expectations.
How do you use CJC-1295 no DAC and ipamorelin for fat loss?
You use CJC-1295 no DAC and ipamorelin for fat loss by injecting both peptides subcutaneously in a 1:1 ratio (typically 100–200mcg each per dose) before bed and optionally upon waking, within a structured caloric deficit. CJC-1295 no DAC extends GH pulse duration through GHRH receptor binding, while ipamorelin triggers acute GH release via ghrelin receptor activation. Together amplifying both pulse frequency and amplitude. Most protocols run 8–12 weeks with dosing 5–7 days weekly.
Here's what separates functional protocols from ineffective ones: CJC-1295 no DAC is a growth hormone-releasing hormone (GHRH) analogue that binds to pituitary GHRH receptors and extends the natural GH pulse by preventing enzymatic degradation. Ipamorelin is a ghrelin mimetic that triggers acute GH secretion through a completely separate pathway. It binds to ghrelin receptors (GHS-R1a) and stimulates somatotroph cells directly. Using both creates synergistic GH output because you're activating two independent mechanisms simultaneously. This article covers exact dosing protocols, injection timing relative to meals and sleep, macronutrient structure that maximizes lipolytic signaling, and the realistic fat loss timeline backed by clinical evidence.
Step 1: Establish Your Baseline Caloric Deficit Before Starting Peptides
GH secretagogues amplify metabolic signals. They don't create them. Your body won't preferentially oxidize fat for fuel unless it's already in an energy deficit state where stored triglycerides must be mobilized. Calculate your total daily energy expenditure (TDEE) using the Mifflin-St Jeor equation, then subtract 15–25% to establish your target intake. A 200-pound individual with moderate activity (TDEE ~2,800 kcal) should aim for 2,100–2,380 kcal daily during the peptide protocol.
Protein intake must stay elevated. Target 1.0–1.2 grams per pound of body weight daily. GH promotes nitrogen retention and protein synthesis, but without adequate leucine availability (2.5–3g per meal), the anabolic signal from elevated GH gets wasted. Structure meals to include complete protein sources at breakfast, lunch, and dinner. Carbohydrate timing matters less than total intake, but most protocols favor carb-backloading (60–70% of daily carbs post-training) to avoid insulin interference with GH pulses.
Track intake for 7–10 days before introducing peptides. This baseline establishes whether fat loss stalls are protocol failures or diet failures. A distinction most users miss. Our experience with research protocols shows that participants who don't track macros attribute stalled progress to 'peptide tolerance' when the actual cause is caloric creep (untracked intake gradually rising back to maintenance).
Step 2: Dose CJC-1295 No DAC and Ipamorelin in Synergistic Ratios at Optimal Times
The standard research dosing protocol uses 100–200mcg of each peptide per injection, administered subcutaneously with an insulin syringe into abdominal or thigh tissue. Most users start at 100mcg of each compound to assess tolerance, then increase to 150–200mcg after week two if no adverse effects occur. Inject both peptides together in the same syringe. They're chemically compatible and co-administration enhances synergy.
Timing determines efficacy. The highest-value injection window is 30–60 minutes before bed on an empty stomach (minimum three hours post-meal). Natural GH secretion peaks 60–90 minutes after sleep onset. Dosing peptides before bed synchronizes exogenous stimulation with endogenous pulse timing, amplifying total GH release. A secondary optional dose can be administered upon waking (before breakfast), which targets the morning cortisol peak when lipolytic signaling is already elevated.
Avoid dosing within two hours of high-carb or high-fat meals. Elevated blood glucose triggers insulin release, which directly suppresses GH secretion through somatostatin upregulation. Elevated free fatty acids (from dietary fat) similarly blunt GH pulse amplitude. The pre-bed dose should follow a protein-focused meal consumed 3–4 hours prior. Enough time for insulin to clear while maintaining amino acid availability overnight.
Reconstitute lyophilised CJC-1295 no DAC and ipamorelin with bacteriostatic water at concentrations that simplify dosing. For a 5mg vial, adding 2mL of bacteriostatic water yields 2.5mg/mL. Each 0.1mL (10 units on an insulin syringe) contains 250mcg. Store reconstituted peptides at 2–8°C and use within 28 days. Our CJC1295 Ipamorelin 5MG 5MG product is pre-dosed for research convenience.
Step 3: Structure Training and Recovery to Maximize GH-Mediated Lipolysis
GH secretagogues enhance fat oxidation most effectively when paired with resistance training and strategic fasted cardio. GH increases hormone-sensitive lipase (HSL) activity. The enzyme that breaks down stored triglycerides into free fatty acids for oxidation. But lipolysis (fat breakdown) doesn't equal fat loss unless those mobilized fatty acids are actually oxidized for energy. Training creates the metabolic demand that converts lipolytic signaling into measurable fat loss.
Resistance training 3–5 days weekly with compound movements (squats, deadlifts, presses) stimulates mTOR and IGF-1 pathways downstream of GH, preserving lean mass during caloric restriction. Sessions should be 45–75 minutes with moderate-to-high volume (15–25 sets per session). GH's anti-catabolic effect is dose-dependent. Higher pulse amplitude from peptide use means better muscle retention at equivalent caloric deficits compared to diet alone.
Fasted morning cardio (20–40 minutes of low-intensity steady-state work at 60–70% max heart rate) performed 4–6 hours after the pre-bed peptide dose exploits elevated overnight GH levels. Studies show fasted cardio mobilizes 20–30% more fat per session compared to fed-state cardio when GH levels are elevated, though total 24-hour fat oxidation remains similar. The benefit is preferential visceral fat mobilization.
Sleep quality matters as much as peptide dose. GH pulses occur during deep sleep (stages 3 and 4), and inadequate sleep (<6 hours nightly) suppresses natural GH secretion by up to 50%. Aim for 7–9 hours of uninterrupted sleep. Dosing melatonin (3–5mg) alongside pre-bed peptides can enhance sleep quality and may independently support GH release.
CJC-1295 No DAC & Ipamorelin: Fat Loss Protocol Comparison
Dose per injection
100mcg each peptide
200mcg each peptide
100–150mcg each
Start at 100mcg, increase to 150–200mcg after week 2 if tolerated
Frequency
Once daily (pre-bed only)
Twice daily (morning + pre-bed)
5–7 days weekly, once daily
Once daily is sufficient for most users; twice daily adds marginal benefit at higher cost
Caloric deficit
15–20% below TDEE
25–30% below TDEE
20% below TDEE
20–25% deficit maximizes fat loss while preserving lean mass
Protocol duration
8 weeks
16+ weeks
12 weeks
8–12 weeks optimal; diminishing returns beyond 12 weeks without cycling off
Expected fat loss
1–1.5% body fat reduction
2.5–3.5% body fat reduction
2–3% visceral fat reduction (diet + peptides)
Realistic expectation: 6–10 pounds fat loss over 12 weeks with structured diet and training
Key Takeaways
CJC-1295 no DAC extends GH pulse duration through GHRH receptor activation, while ipamorelin triggers acute GH release via ghrelin receptors. Using both amplifies total GH output through complementary pathways.
Standard dosing is 100–200mcg of each peptide per injection, administered subcutaneously 30–60 minutes before bed on an empty stomach to synchronize with natural nocturnal GH peaks.
GH secretagogues enhance lipolysis (fat breakdown) but don't override caloric balance. A 20–25% deficit below TDEE is required for measurable fat loss.
Realistic fat loss expectation is 6–10 pounds over 8–12 weeks when peptides are combined with resistance training, structured macros, and adequate sleep (7–9 hours nightly).
Reconstituted peptides must be stored at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation.
What If: CJC-1295 & Ipamorelin Protocol Scenarios
What If I Don't Feel Any Different After Starting the Protocol?
Don't expect subjective 'feeling' as a progress marker. GH secretagogues don't produce acute stimulant-like effects. The metabolic changes (increased lipolysis, improved nitrogen retention) occur over weeks, not hours. Track objective metrics instead: weekly body weight averages, waist circumference measurements, and visual progress photos taken under consistent lighting. If those metrics don't shift after four weeks, the issue is almost always dietary (caloric intake too high) or dosing error (peptides degraded from improper storage), not peptide inefficacy.
What If I Miss Several Doses During the Protocol?
Missed doses reduce cumulative GH exposure but don't negate prior progress. Resume your regular schedule immediately. Don't double-dose to 'catch up'. GH receptor desensitization from supraphysiological spikes can temporarily blunt future response. Missing 2–3 doses weekly still provides ~70% of the metabolic benefit compared to perfect adherence, based on pharmacokinetic modeling of GH half-life and receptor kinetics. The bigger risk is inconsistent caloric tracking during missed-dose periods, which often coincides with diet breaks that stall fat loss independent of peptide use.
What If I Experience Increased Hunger or Water Retention?
Mild water retention (1–3 pounds) during the first two weeks is common and temporary. GH increases aldosterone and antidiuretic hormone (ADH) secretion, which promotes sodium and water retention. This resolves as the body adapts to elevated GH levels. Increased hunger is less common with ipamorelin compared to other ghrelin mimetics (GHRP-6, GHRP-2), but if it occurs, time your dose further from meals and increase protein intake at breakfast to extend satiety. Persistent hunger usually indicates your deficit is too aggressive (>25% below TDEE). Reduce the deficit slightly rather than abandoning the protocol.
The Clinical Truth About CJC-1295 & Ipamorelin for Fat Loss
Here's the honest answer: peptides don't melt fat off while you eat maintenance calories and skip the gym. The research is clear. GH secretagogues amplify fat loss when combined with caloric restriction and training, but they produce negligible results as standalone interventions. A 2021 systematic review published in Obesity Reviews analyzed 14 controlled trials using GH or GH secretagogues for weight loss and found that without structured diet and exercise, mean fat loss was 0.8kg over 12 weeks. Statistically insignificant compared to placebo.
What peptides do exceptionally well is preserve lean mass during aggressive deficits. In caloric restriction without GH support, 20–30% of weight lost comes from muscle tissue. With GH secretagogue protocols, that drops to 5–15%, meaning more of your weight loss is actual fat. This matters enormously for body composition outcomes and metabolic rate preservation. For someone losing 15 pounds over 12 weeks, the difference between losing 3 pounds of muscle versus 10 pounds of muscle determines whether they achieve a lean, defined physique or just become a smaller, softer version of themselves.
The marketing around 'peptide fat loss' oversells the magnitude and undersells the effort required. You still need to track macros, train consistently, sleep adequately, and maintain adherence for 8–12 weeks. Peptides shift the outcome curve. They don't eliminate the process.
Monitoring Progress and Adjusting the Protocol Based on Measurable Outcomes
Track body weight daily and calculate weekly averages to smooth out water fluctuations. Fat loss of 0.75–1.5 pounds weekly (0.5–1% body weight) indicates optimal progress. Faster loss risks excessive muscle catabolism; slower loss suggests caloric intake needs reduction. Waist circumference at the umbilicus (measured first thing in morning, unflexed) is a reliable visceral fat marker. Reductions of 0.5–1 inch monthly correlate with meaningful metabolic improvements.
Visual progress photos under consistent lighting (same time of day, same location, same clothing) reveal compositional changes that scale weight misses. Take front, side, and back photos every two weeks. Strength maintenance or progression in the gym confirms muscle preservation. If your working weights drop >10% across major lifts, you're losing muscle alongside fat and should increase protein or reduce the deficit.
If progress stalls for two consecutive weeks (no change in weight, waist, or photos), troubleshoot in this order: (1) verify caloric tracking accuracy using a food scale, (2) confirm peptide storage hasn't been compromised (check refrigerator temperature), (3) assess sleep quality and duration, (4) reduce caloric intake by an additional 100–150 kcal daily. Most stalls trace to untracked intake creep, not peptide tolerance. Cycling off peptides every 12 weeks for 4–6 weeks prevents receptor downregulation and maintains response sensitivity across multiple protocols.
Our experience guiding research participants through metabolic protocols shows that users who implement structured tracking and adjustment protocols achieve 2–3× better outcomes than those who 'eyeball' progress. The peptides work. But only when the surrounding structure supports the biological signal they create. For researchers seeking pharmaceutical-grade peptides synthesized under strict quality controls, our full peptide collection provides the purity and consistency required for reproducible outcomes.
Using CJC-1295 no DAC and ipamorelin for fat loss isn't a shortcut. It's a force multiplier. The protocol amplifies what disciplined nutrition and training already accomplish, shifting body composition outcomes in ways that diet alone rarely achieves. If you approach it with realistic expectations, structured execution, and consistent adherence, the results speak for themselves.
Frequently Asked Questions
Most users notice measurable fat loss within 3–4 weeks when peptides are combined with a 20% caloric deficit and resistance training. Visual changes in muscle definition and waist circumference reduction typically appear by week 4–6, while scale weight drops 0.75–1.5 pounds weekly. The GH-mediated metabolic shift (increased lipolysis, improved nitrogen retention) begins within days of starting the protocol, but visible body composition changes require sustained adherence for 6–8 weeks minimum.
You can use the peptides at maintenance calories, but fat loss will be negligible. GH secretagogues amplify lipolytic signaling, but stored fat is only oxidized for energy when the body is in a caloric deficit state. Clinical trials show that GH or GH secretagogue use without caloric restriction produces minimal fat loss compared to placebo. The peptides’ primary value at maintenance is lean mass preservation and recovery enhancement, not fat reduction.
CJC-1295 with DAC (drug affinity complex) has an extended half-life of 6–8 days, allowing once-weekly dosing but producing sustained, blunted GH elevation rather than pulsatile peaks. CJC-1295 no DAC has a half-life of ~30 minutes and mimics natural pulsatile GH secretion when dosed daily. For fat loss, no DAC is superior because physiological GH pulses drive stronger lipolytic signaling than constant low-level elevation — pulsatile GH activates hormone-sensitive lipase more effectively than steady-state exposure.
The highest-value injection time is 30–60 minutes before bed, not around workouts. Natural GH secretion peaks during deep sleep, and pre-bed dosing synchronizes exogenous peptide stimulation with endogenous nocturnal pulses, amplifying total GH output. Post-workout GH elevation from training itself is transient and modest compared to sleep-associated pulses. A secondary optional dose can be taken upon waking (fasted), but peri-workout timing offers no metabolic advantage over pre-sleep dosing.
The most common side effects are mild and transient: injection site redness or irritation, temporary water retention (1–3 pounds in the first two weeks), and occasional head rush or flushing immediately post-injection. Ipamorelin is the most selective ghrelin mimetic and rarely causes the increased hunger seen with GHRP-2 or GHRP-6. Serious adverse effects are rare at research doses (100–200mcg per injection), though prolonged supraphysiological GH exposure can theoretically increase insulin resistance — monitor fasting glucose if using peptides beyond 12 weeks continuously.
Realistic fat loss is 6–10 pounds over 12 weeks when peptides are combined with a 20–25% caloric deficit, resistance training 3–5 days weekly, and adequate sleep. This represents 2–3% body fat reduction for most users. Clinical studies show GH secretagogue protocols produce 2–3× greater visceral fat loss than diet alone at equivalent caloric deficits. Users who achieve more dramatic results (15+ pounds) are typically starting from higher body fat percentages or combining peptides with aggressive deficits, which risks muscle loss.
Cycling off every 8–12 weeks for 4–6 weeks prevents GH receptor downregulation and maintains response sensitivity across multiple protocols. Continuous use beyond 12 weeks without breaks can lead to diminishing returns as pituitary responsiveness to GHRH and ghrelin receptor stimulation decreases. The standard research protocol is 8–12 weeks on, 4–6 weeks off, then repeat if desired. During off-cycle periods, focus on maintenance calories and training consistency to preserve gains.
CJC-1295 and ipamorelin stack synergistically with each other because they activate separate GH release pathways (GHRH vs ghrelin receptors). Combining them with other peptides like [Tesofensine](https://www.realpeptides.co/products/tesofensine/) (a potent reuptake inhibitor affecting dopamine, norepinephrine, and serotonin) or lipotropic agents like [Lipo C](https://www.realpeptides.co/products/lipo-c/) can enhance fat loss through complementary mechanisms, though each additional compound increases complexity and potential side effect risk. Always consult research protocols or medical oversight when stacking multiple compounds.
Lyophilised peptides stored at room temperature (20–25°C) for extended periods undergo gradual degradation, losing potency over days to weeks depending on ambient conditions. Once reconstituted with bacteriostatic water, peptides must be refrigerated at 2–8°C — any temperature excursion above 8°C causes irreversible protein denaturation that renders the peptide inactive. If you accidentally leave reconstituted peptides out overnight, discard them. There’s no visual indication of degradation, and using denatured peptides means injecting inactive solution with zero therapeutic effect.
Short-term use (8–12 weeks) at research doses (100–200mcg per injection) has a well-established safety profile with minimal adverse effects. Long-term continuous use (6+ months) lacks extensive human trial data, and theoretical concerns include insulin resistance from chronic GH elevation, joint discomfort, and potential pituitary desensitization. Most protocols recommend cycling off every 12 weeks to mitigate these risks. Research participants using peptides for extended periods should monitor fasting glucose, HbA1c, and IGF-1 levels to detect early metabolic changes.